CEFEPIME- cefepime hydrochloride injection, powder, for solution Estados Unidos - inglês - NLM (National Library of Medicine)

cefepime- cefepime hydrochloride injection, powder, for solution

sagent pharmaceuticals - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g - cefepime for injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae , including cases associated with concurrent bacteremia, pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. cefepime for injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies (14.1)] . cefepime for injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of escherichia coli or klebsiella pneumoniae , when the infec

Cefepime Mylan Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

cefepime mylan

viatris limited - cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base; cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base - powder for injection - 1 g - active: cefepime dihydrochloride monohydrate 1.1518 g equivalent to 1 g cefepime free base excipient: arginine active: cefepime dihydrochloride monohydrate 1.189 g equivalent to 1 g cefepime free base excipient: arginine - cefepime mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · lower respiratory tract infections, including pneumonia and bronchitis. · urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · skin and skin structure infections. · septicaemia. · intra-abdominal infections, including peritonitis and biliary tract infections. · empiric treatment of febrile neutropenia.

Cefepime Mylan Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

cefepime mylan

viatris limited - cefepime dihydrochloride monohydrate 2.30368 g equivalent to 2 g cefepime free base; cefepime dihydrochloride monohydrate 2.378 g equivalent to 2 g cefepime free base - powder for injection - 2 g - active: cefepime dihydrochloride monohydrate 2.30368 g equivalent to 2 g cefepime free base excipient: arginine active: cefepime dihydrochloride monohydrate 2.378 g equivalent to 2 g cefepime free base excipient: arginine - cefepime mylan is indicated in adults for the treatment of the infections listed below when caused by susceptible bacteria. · lower respiratory tract infections, including pneumonia and bronchitis. · urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections. · skin and skin structure infections. · septicaemia. · intra-abdominal infections, including peritonitis and biliary tract infections. · empiric treatment of febrile neutropenia.

CEFEPIME injection, powder, for solution Estados Unidos - inglês - NLM (National Library of Medicine)

cefepime injection, powder, for solution

apotex corp. - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g - cefepime for injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae , including cases associated with concurrent bacteremia, pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. cefepime for injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies (14.1) ]. cefepime for injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of escherichia coli or klebsiella pneumoniae , when the infec

CEFEPIME injection, powder, for solution Estados Unidos - inglês - NLM (National Library of Medicine)

cefepime injection, powder, for solution

apotex corp. - cefepime hydrochloride (unii: i8x1o0607p) (cefepime - unii:807pw4vqe3) - cefepime 1 g - cefepime for injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae , including cases associated with concurrent bacteremia, pseudomonas aeruginosa , klebsiella pneumoniae , or enterobacter species. cefepime for injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. in patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see clinical studies (14.1) ]. cefepime for injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of escherichia coli or klebsiella pneumoniae , when the infec

BINDOZEF INJECTION 2g cefepime (as hydrochloride) 2 g powder for injection vial Austrália - inglês - Department of Health (Therapeutic Goods Administration)

bindozef injection 2g cefepime (as hydrochloride) 2 g powder for injection vial

strides pharma science pty ltd - cefepime, quantity: 2000 mg - injection, powder for - excipient ingredients: arginine - adults:. cefepime is indicated in the treatment of the infections listed below when caused by susceptible bacteria.. - lower respiratory tract infections, including pneumonia and bronchitis;. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - intra-abdominal infections, including peritonitis and biliary tract infections;. - gynaecological infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. cefepime is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered.. paediatrics:. cefepime is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria. . - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empirical therapy with cefepime may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.. because of its broad spectrum of bactericidal activity against gram positive and gram negative bacteria, cefepime can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime. in patients who are at risk of mixed aerobic/ anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.

BINDOZEF INJECTION 1g cefepime (as hydrochloride) 1 g powder for injection vial Austrália - inglês - Department of Health (Therapeutic Goods Administration)

bindozef injection 1g cefepime (as hydrochloride) 1 g powder for injection vial

strides pharma science pty ltd - cefepime, quantity: 1000 mg - injection, powder for - excipient ingredients: arginine - adults:. cefepime is indicated in the treatment of the infections listed below when caused by susceptible bacteria.. - lower respiratory tract infections, including pneumonia and bronchitis;. - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - intra-abdominal infections, including peritonitis and biliary tract infections;. - gynaecological infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. cefepime is also indicated for surgical prophylaxis in patients undergoing intra-abdominal surgery. in this indication it is essential that metronidazole also be administered.. paediatrics:. cefepime is indicated in paediatric patients over 2 months of age for the treatment of the infections listed below when caused by susceptible bacteria. . - urinary tract infections, both complicated, including pyelonephritis, and uncomplicated infections;. - skin and skin structure infections;. - septicaemia;. - empirical treatment in febrile neutropenic patients (see precautions).. culture and susceptibility studies should be performed when appropriate to determine susceptibility of the causative organism(s) to cefepime. empirical therapy with cefepime may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.. because of its broad spectrum of bactericidal activity against gram positive and gram negative bacteria, cefepime can be used appropriately as monotherapy prior to identification of the causative organisms(s). in the treatment of febrile neutropenia, consideration should be given to the need for other antibiotics in combination with cefepime. in patients who are at risk of mixed aerobic/ anaerobic infection, including infections in which bacterioides fragilis may be present, concurrent initial therapy with an anti-anaerobic agent is recommended before the causative organism(s) is known.